This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background on the Grants Program Launched as part of the Orphan Drug Act of 1983, this program aims to encourage research and development of drugs, biologics, medical devices, and medical foods for rare diseases, defined as conditions that affect fewer than 200,000 people in the U.S. The seven awardees included six early-stage trials (e.g.,
Jefferson researchers find that the genetic underpinnings of a skin disorder at birth indicate future heart problems PHILADELPHIA – Our skin tells us when we’ve spent too much time in the sun or when the dry air of winter has sucked away too much moisture.
Throughout 2020, IQVIA data, both secondary and primary research pointed to often substantial share of non-COVID-19 patients receiving no, or suboptimal treatment. The non COVID-19 patient backlog which has built across conditions and countries is something addressed in another in-depth article for pharmaphorum.
COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Topline results will be presented at the American College of Cardiology 70th Annual Scientific Session. Adakveo sales reached USD 37 million. The safety profile of Entresto was confirmed.
We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. This acquisition also signifies the establishment of the company’s first research center outside the US. billion RMB ($34.47 billion USD) in 2022, a 7.49
I am proud of the truly transformational science that our research and clinical teams are bringing to the fight against disease, as well as the unprecedented speed with which we are advancing our clinical programs in the battle against COVID-19. THERAPEUTIC AREAS OF FOCUS. Inflammation and Immunology. and -50.4%
To maximize audience engagement, pharma brands should create peer-reviewed research summaries highlighting key findings from clinical trials, webinars and virtual conferences featuring leading medical experts discussing treatment advancements, and interactive case studies that allow HCPs to apply knowledge in real-world scenarios.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content